Market Research ReportDec 2, 2022

Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Research Report: Size, Share, Trend Analysis Type (IBS-D, IBS-C, IBS-M), Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), End User (Hospitals, Clinics, Research Laboratories, End User_Others) and By Region (Middle East and Africa, North America, Asia Pacific, Europe, South America) - Growth Outlook & Industry Forecast To 2023

Vertical: HealthcareBase Year: 201711 Sections

Book Demo

Executive Summary

Irritable Bowel Syndrome Treatment Market — Snapshot

Market Size (2017)
$1.89B
Projected (2023)
$2.99B
CAGR (2015–2023)
8.8%
Key Players
10+

Irritable bowel syndrome (IBS) is a global issue, with 5 to 15% of the total population experiencing symptoms that would satisfy the definition of IBS. In a systematic review of the global prevalence of IBS, in 2015 Lovell and Ford documented a collective prevalence of 11% with all regions of the world anguishing from this disorder at parallel rates. Moreover, irritable bowel syndrome affects 10 to 15% of the US population to some degree. This condition is characterized by stomach pain and distress with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical clarification for these symptoms. Irritable bowel syndrome is anticipated to affect women more than men and is most common in patients ranging from 30 to 50 years of age.

The global irritable bowel syndrome treatment market is growing at a rapid pace. The global irritable bowel syndrome treatment market is expected to reach USD 2,988.6 million by 2023 from USD 1,890.9 million in 2017 and is expected to register a CAGR of 7.58% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with 45% share, followed by Europe and Asia-Pacific with shares of 28.8% and 18.4%, respectively.

The market has been segmented based on type, drug type, end-user, and region.

The global irritable bowel syndrome treatment market on the basis of type has been segmented into IBS-D, IBS-C, and IBS-M. The IBS-D segment accounted for the largest market share of 57.9% in 2017, with a market value of USD 1095.8 million, which is projected to register a CAGR of 8.31% during the forecast period.

The market based on the drug type has been segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. The linaclotide segment accounted for the largest market share of 31.63% in 2017, with a market value of USD 598.1 million, which is projected to register the CAGR of 7.95%.

The global irritable bowel syndrome treatment market, on the basis of end-user has been segmented into hospitals, clinics, and research laboratories. The hospitals segment accounted for the largest market share of 41.19% in 2017, with a market value of USD 778.9 million, which is projected to register a CAGR of 8.04% over the assessment period.

Key Insight

The Irritable Bowel Syndrome Treatment Market market is projected to grow at a CAGR of 8.8% from 2015 to 2023.

Market Performance Trend

Historical performance and future projections (2020–2030, USD Billion)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Scope & Coverage

What this report covers

Geographic Coverage: This analysis covers 5 regions: Middle East and Africa, North America, Asia Pacific, Europe, South America.
Market Segmentation: The market is analyzed across 3 segments: IBS-D, IBS-C, IBS-M. Forecasts are provided for each segment from 2015 to 2023.
Competitive Landscape: 10 leading companies are profiled, covering market positioning, strategies, and recent developments.

Market Size (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Overview

Irritable Bowel Syndrome Treatment Market — Growth Trajectory

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder which is characterized by repeated pain in abdomen and changes in the bowel movement which can be diarrhea, constipation, or both. Irritable bowel syndrome is expected to affect women more than men and is most common in patients aged 30 to 50 years. The symptoms of IBS vary in severity and duration from person to person. The market growth is majorly due to factors such as increasing prevalence of IBS, increasing prevalence of anxiety, a strong pipeline of drugs for IBS, and rising prevalence of depression.

Irritable Bowel Syndrome Treatment Market — Growth Trajectory

IBS-D

IBS-C

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Size Trend (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Dimensions

How this market is segmented

Type is analyzed as a distinct market dimension.
Drug Type is analyzed as a distinct market dimension.
End User is analyzed as a distinct market dimension.

Geographic Analysis

Regional market breakdown

Middle East and Africa market size reached $119.00M in 2015 and is projected to reach $205.80M by 2023, growing at a CAGR of 7.1%.
North America market size reached $528.10M in 2015 and is projected to reach $1.07B by 2023, growing at a CAGR of 9.3%.

Asia Pacific market size reached $279.40M in 2015 and is projected to reach $514.80M by 2023, growing at a CAGR of 7.9%.
Europe market size reached $437.10M in 2015 and is projected to reach $851.90M by 2023, growing at a CAGR of 8.7%.
South America market size reached $160.20M in 2015 and is projected to reach $344.00M by 2023, growing at a CAGR of 10.0%.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Research Methodology

Irritable Bowel Syndrome Treatment Market — How We Researched This Market

This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.

Base Year
2017
Historical Period
2015 – 2016
Forecast Period
2018 – 2023
Primary Interviews
150+

Research Process

Historical data (2015–2017) and forecast period (2017–2023)

Problem Definition

Market scoping
Objective setting
Framework design

Secondary Research

Literature review
Data mining
Trend analysis

Primary Research

Expert interviews
Field visits
Surveys

Data Analysis

Quantitative modeling
Statistical testing
Validation

Insights & Reporting

Synthesis
Recommendations
Visualization

Research Depth

Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.

Historical vs. Forecast Data

Historical (observed)

Forecast (modelled)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Competitive Landscape & Porter's Five Forces

Irritable Bowel Syndrome Treatment Market — Competitive Analysis

The global irritable bowel syndrome treatment market is dominated by several market players such as Allergan, Ironwood Pharmaceuticals, Valeant Pharmaceuticals International, Inc., Mallinckrodt, and others. The major players in the irritable bowel syndrome market are opting for new product launches, strategic collaborations, and partnerships to brace their position in the market.

Allergan and Ironwood Pharmaceuticals, both collectively accounted for the largest share of 46.5% in the global irritable bowel syndrome treatment market in the year 2017. Allergan has successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. High customer satisfaction level, exceptional performance in new markets, and strong brand portfolio add to the company’s competitive advantage. Similarly, Ironwood Pharmaceuticals employs a strategy of focusing on rare and severe diseases, maintaining the quality of the products by maximum automation and rising investment on research and development which helps the company in maintaining its market position. The company’s major share is due to its blockbuster product LINZESS, a drug which is used for the treatment of irritable bowel syndrome. Additionally, the company is engaged in strategic collaborations which facilitates it to strengthen its position and expand its market presence globally. For instance, Ironwood's partner Astellas Pharma, Inc. is commercializing LINZESS for adults with IBS-C in Japan.

Valeant Pharmaceuticals International, Inc. held the second largest share of 28% in the global irritable bowel syndrome treatment market in the year 2017. The company develops, manufactures, and markets a wide range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology, and branded generics. Furthermore, the company is engaged in strategic collaborations and mergers which helps the company to hold its market position. For instance, in February 2015, the company acquired Salix Pharmaceuticals, a specialty pharmaceutical company devoted to developing and commercializing prescription drugs and medical devices used in the treatment of a variety of GI disorders with a portfolio of over 20 marketed products, including Xifaxan, which is used in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men, in traveller's diarrhea caused by E. coli, as well as in the reduction in risk of overt hepatic encephalopathy recurrence. As published in the annual report of the company in 2017, Xifaxan contributed to 11% of the total product sales.

Mallinckrodt held the third largest share of 6.3% in the year 2017. This was majorly due to its product Amitiza, which is used to treat idiopathic chronic constipation and irritable bowel syndrome. The company focuses on mergers and acquisitions to expand its market. For instance, in February 2018, Mallinckrodt acquired Sucampo Pharmaceuticals, a global biopharmaceutical company. This strategy of the company aims to expand its specialty brands segment.

Astellas Pharma, Inc. is also a prominent player in the irritable bowel syndrome treatment market. It has a worldwide presence with its own distribution channels in more than 50 countries around the world. The company works in therapeutic segments such as oncology, immunology, neuroscience, ophthalmology, and other areas. In March 2017, the company announced the launch of LINZESS tablets for the treatment of irritable bowel syndrome. The company has several products in the pipeline for various therapeutic areas. For instance, in January 2017, Astellas Pharma, Inc. and its strategic partner Ironwood Pharmaceuticals, Inc. reported positive data from Phase III clinical trial of linaclotide in adult patients with chronic constipation in Japan.

Apart from the major players in the irritable bowel syndrome treatment market, some other players such as Lexicon Pharmaceuticals, Ardelyx, Inc., Nestle Health Sciences, Synergy Pharmaceuticals, Abbott, and few others collectively held 19.2% market share in the global market in 2017.

Bargaining Power of Suppliers

Bargaining power of suppliers in the irritable bowel syndrome treatment market is medium. The suppliers in the market are manufacturers and suppliers of IBS treatment products. Currently, the market is dominated by few existing major companies and they have the capability of fluctuating the costs of the products. Switching cost of these suppliers is medium as suppliers tend to enter into long-term associations, partnership and deals with the drug manufacturing companies. The overall bargaining power of suppliers in the global irritable bowel syndrome treatment market is medium.

Bargaining Power of Buyers

The bargaining power of buyers is medium in the global irritable bowel syndrome treatment market owing to the growing prevalence of IBS globally. The buyers in the market are majorly inclined towards the brand identity. Additionally, the buyers can exert moderate pressure on the companies in this market as some companies provide their products at a high cost.

Threat of New Entrants

The threat of new entrants is low to medium in the global irritable bowel syndrome treatment market. Any IBS drugs manufacturing company trying to enter the global market is required to abide by mandatory regulatory standards. Prevalence of irritable bowel syndrome is increasing significantly, which has increased the demand for new drugs. Additionally, available drugs did not show long-term effects and thus manufactures are focusing on research and development. Moreover, the introduction of new drugs requires a long-time clinical trial and a huge capital which creates a difficult scenario for new entrants in the market.

Threat of Substitutes

The threat of substitutes in the global irritable bowel syndrome treatment market is medium. There are few substitutes available in the market, and buyer propensity to substitute is low to medium. However, the quality and trust issue and excellent service provided by the existing players restrict the threat by the substitutes.

Intense Rivalry

The degree of competition in the global irritable bowel syndrome treatment market is medium to high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Additionally, the companies involved in irritable bowel syndrome treatment market are trying to introduce new effective treatments for different IBS types for differentiating their product from their rivals.

Quantitative Analysis

Regional Breakdown

Regional market breakdown for Irritable Bowel Syndrome Treatment Market.

Regional Market Size (USD Mn)

Market estimates by geography (2023)

USD Mn

InsightNorth America leads with $1.07B by 2023, while South America is projected to grow fastest at a 10.0% CAGR.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Regional Market Data

REGION	2015	2017	2023	CAGR	SHARE
Middle East and Africa	$119.00M	$172.00M	$205.80M	7.1%	7%
North America	$528.10M	$784.30M	$1.07B	9.3%	36%
Asia Pacific	$279.40M	$413.80M	$514.80M	7.9%	17%
Europe	$437.10M	$652.10M	$851.90M	8.7%	29%
South America	$160.20M	$234.60M	$344.00M	10.0%	12%
Total	$1.52B	$2.26B	$2.99B	8.8%	100%

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Segment Revenue (2023)

IBS-D

IBS-C

IBS-M

00.511.52

IBS-D60%
IBS-C22%
IBS-M18%

Total Market Size

$2.99B

Market by Segment (2023)

APPLICATION	REVENUE ($B)	GROWTH RATE	MARKET PENETRATION
IBS-D	$1.79B	9.2%	60%
IBS-C	$650.20M	8.4%	22%
IBS-M	$547.90M	7.9%	18%

* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Empower your Business
with Insights

Save over 20% on
Annual Subscription

Subscribe now

Book a demo

See plans for professionals or small and medium businesses.

Analytics

Irritable Bowel Syndrome Treatment Market — Key Findings

Analytical insights on Irritable Bowel Syndrome Treatment Market covering market dynamics, competitive landscape, and strategic outlook.

Key Analytical Findings

The Irritable Bowel Syndrome Treatment Market market is projected to reach $2.99B by 2023, growing at 8.8% CAGR. The IBS-D segment holds the largest share.

Market Dynamics

Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal (GI) disorder that affects millions of people worldwide. In this disorder, the large intestine is affected which further leads to abdominal pain, bloating, diarrhea, and cramping. IBS may negatively affect the daily routine life such as work, sleep, diet, ability to travel, sexual function, and personal relationships. There is a significant economic burden owing to the growing prevalence of IBS, as IBS causes both losses in work productivity of the patient and high healthcare costs. Factors such as rising prevalence of anxiety, strong drug pipeline, and increasing prevalence of depression are major drivers propelling the market growth.

Market Drivers

Anxiety is considered to be a leading cause of IBS as it leads to abdominal cramps and pain. According to a report by the World Health Organization (WHO), the portion of the global population with anxiety disorders was estimated to be 3.6% in 2015. It also stated that in the year 2015 the total estimated number of people living with anxiety disorders globally was about 264 million. According to the same source, in 2015, about 36.17 million cases of anxiety disorders were reported in the European region. According to the updated report by the Anxiety and Depression Association of America, in 2017, approximately 30% of the adult population in North America had anxiety disorders. Moreover, anxiety acts as a trigger for IBS symptoms in many people. According to a survey carried out by the Gastrointestinal Society in 2016, about 32% IBS patients had some form of mood disorders, 27% had the gastroesophageal reflux disease, and 27% had anxiety disorders. Furthermore, as anxiety is related to irritable bowel syndrome, the increasing prevalence of anxiety is expected to provide favorable background for the market to grow over the forecast period.

Market Opportunities

The growing reimbursements for IBS in certain developed countries such as the US are expected to provide huge opportunities for the market growth in the future. In the US, the prevalence of IBS is increasing owing to which Medicare provides reimbursement in certain cases. In general, Medicare covers all medically necessary tests required for the diagnosis of IBS. In addition to this, there is a limited coverage for prescript medications under Original Medicare (Part A and Part B). However, if the patient has a Medicare Part D Prescription Drug Plan, medications for irritable bowel syndrome may be covered. Additionally, some of the private insurance companies provide life insurance for patients with IBS. For Instance, the JRC Insurance Group based in California provides life insurance to people with irritable bowel syndrome. Moreover, some companies also provide medical travel insurances for people with irritable bowel syndrome. For instance, TICORP Limited under its trade name Staysure provides travel insurance for people with IBS. The company looks after the patient in the event of a medical emergency while away from home country. In addition to this, the company has operations in the US, the UK, and Canada. Thus, the improving reimbursement scenario for irritable bowel syndrome is expected to contribute to the market growth.

Market Restraints

Strict government regulations for the approval of drugs or treatments for IBS may hamper the market growth over the forecast period. The US Food Drug and Administration (FDA) is a globally renowned regulatory body engaged in monitoring and approving drugs and medical devices. This regulatory body strictly regulates the treatment products developed for irritable bowel syndrome. For instance, in May 2015, Viberzi got the approval for the treatment for IBS-D, whereas, in February 2017, FDA advised discontinuing Viberzi for patients who do not have a gallbladder, after getting the report of 120 serious cases of pancreatitis or death. Thus, market players have challenges to develop another treatments for IBS-D. Moreover, the European Medicines Agency (EMA) is a decentralized agency of the European Union which is responsible for scientific evaluation, supervision, and safety monitoring of medicines in the European Union (EU). The European medicines regulatory network is a closely coordinated regulatory network of national competent authorities in the Member States of the European Economic Area (EEA) working together with EMA and the European Commission. Thus, for the launch of new treatments for IBS the company is required to get an approval from the European medicine regulatory network. Additionally, continuous changes in norms of regulatory bodies operating globally can affect the growth of the market. Moreover, strict legal formalities create problems for market players to introduce new treatment options for IBS.

Strategic Outlook and Future Directions

Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.

Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.

Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.

Market Value by Segment (2023)

Value (USD Mn)

IBS-D

IBS-C

IBS-M

Companies

Key companies profiled in Irritable Bowel Syndrome Treatment Market

Profiles of 105 companies operating in the Irritable Bowel Syndrome Treatment Market market, including revenue, employee count, and market positioning where available.

Region

Industry

Founded Year

Showing 105 of 105 companies

Nestle Hea

Nestle Health Science

Healthcare

Company Headquarters: Vevey, Switzerland Founded: 1905 Workforce: 328,000 + employees (2017) Company Working: The company is focusing on developing the world's best products and services for all stages of life helping people and their families. The company produces approximately a billion science-based nutritional solutions per year which are available through retail and pharmacy outlets or recommended by healthcare professionals in institutions, which addresses a spectrum of health conditions from pediatric allergy to malnutrition amongst the frail elderly.

Company Headquarters: Dublin, Ireland Founded: 2013 Workforce: ~16,900 Company Working: Allergan is a leading global pharmaceutical company. The company is engaged in the manufacturing and commercialization of hyaluronic acid for medical products, devices, biologics, and surgical products for patients across the world. It operates through three business segments, namely US Specialized Therapeutics, US General Medicine, and International. The company sells its products primarily to the retailers and distributors including food store chains and national retail drug. The prime customers are hospitals, clinics, and government agencies as well as managed healthcare providers, such as health maintenance organizations and other institutions. The company has operations in 100 countries. The US and Canada account for around 10% of the company’s revenue. The three prominent customers of the company are McKesson Corporation, which accounted for around 25% of the sales revenue; Cardinal Health, Inc with 23%; and AmerisourceBergen Corporation with 22% in 2018. In addition, the company has development and manufacturing centers of raw materials, intermediate ingredients, and active pharmaceutical ingredients. Its manufacturing plants are located in Ireland, the US, Brazil, Belgium, France, and Costa Rica.

Mallinckrodt

Company Headquarter: US Founded: 1840 Workforce: 1000 to 5000 Employees Company Working: Mallinckrodt is a specialty pharmaceuticals company which develops, manufactures, markets, and distributes specialty pharmaceutical drugs and therapies. The company focuses on underserved patients of neurology, rheumatology, nephrology, pulmonology, and ophthalmology. The company also focuses on immunotherapy, neonatal respiratory critical care therapies, analgesics, and gastrointestinal products.

United States, North America

Ironwood P

Ironwood Pharmaceuticals

Healthcare

Company Headquarter: Massachusetts, US Founded: 1998 Workforce: 730 Employees Company Working: Ironwood Pharmaceuticals is a commercial biotechnology company. The company commercializes two innovative primary care products, namely, linaclotide, the US branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, for the treatment of hyperuricemia associated with gout. It also has a pipeline of innovative product candidates in areas of significant unmet needs, including uncontrolled gastroesophageal reflux disease, diabetic nephropathy, achalasia, heart failure with preserved ejection fraction, and sickle-cell anemia.

United States, North America

Synergy Ph

Synergy Pharmaceuticals Inc.

Healthcare

Company Headquarter: New York, US Founded: 2005 Workforce: 155+ employees Company Working: Synergy Pharmaceuticals Inc. is a biopharmaceutical company which focuses on the development and commercialization of novel gastrointestinal therapies. The company holds 100% worldwide rights to the proprietary uroguanylin based GI platform that includes one commercial product, TRULANCE (plecanatide), and a second lead product candidate, dolcanatide.

United States, North America

Novavax, I

Novavax, Inc.

Healthcare

Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa

Page 1 of 18

…

Go to page

Charts

12 interactive charts drawn from the Irritable Bowel Syndrome Treatment Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.

Pro

Healthcare & PharmaJul 31, 2026

Global Irritable Bowel Syndrome Treatment Market South America Of South America

Pro

Healthcare & PharmaJul 31, 2026

Global Irritable Bowel Syndrome Treatment Market Germany, Spain, France, United Kingdom, Italy, Eastern-Europe and Rest Of Western Europe Of Europe By Country

Pro

Healthcare & PharmaJul 31, 2026

Global Irritable Bowel Syndrome Treatment Market Australia, China, India, Japan, South Korea and Rest Of Asia Pacific By Country

Pro

Healthcare & PharmaJul 31, 2026

Global Irritable Bowel Syndrome Treatment Market United States and Canada Of North America By Country

Pro

Healthcare & PharmaJul 31, 2026

Global Irritable Bowel Syndrome Treatment Market Middle-East and Africa Of Middle East And Africa

Pro

Healthcare & PharmaJul 31, 2026

Global Irritable Bowel Syndrome Treatment Market By Region

Browse All Charts

About the Author

Healthcare Research Team

Healthcare

Our healthcare desk at Wantstats is staffed by a mix of clinical-market analysts and a senior researcher who track drug approvals, device launches, and provider economics as they happen — not just at reporting time. Every figure in this report is checked against primary interviews, regulatory filings, and our own proprietary datasets before it goes to print.

Similar Reports

View all

HealthcareJul 31, 2026

Stoma Ostomy Care Market

HealthcareJul 31, 2026

Ready-to-eat Popcorn Market

HealthcareJul 31, 2026

Organoids and Spheroids Market

Powering the world's best teams.
From next-gen startups to established enterprises.

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market Research Report: Size, Share, Trend Analysis Type (IBS-D, IBS-C, IBS-M), Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), End User (Hospitals, Clinics, Research Laboratories, End User_Others) and By Region (Middle East and Africa, North America, Asia Pacific, Europe, South America) - Growth Outlook & Industry Forecast To 2023

Starting from

$4,950

Irritable Bowel Syndrome Treatment Market

Key Insight

Market Performance Trend

Market Scope & Coverage

What this report covers

Irritable Bowel Syndrome Treatment Market — Growth Trajectory

Market Size Trend (USD Mn)

Market Dimensions

How this market is segmented

Geographic Analysis

Regional market breakdown

Problem Definition

Secondary Research

Primary Research

Data Analysis

Insights & Reporting

Research Depth

Historical vs. Forecast Data

Competitive Landscape & Porter's Five Forces

Irritable Bowel Syndrome Treatment Market — Competitive Analysis

Regional Market Data

Segment Revenue (2023)

Segment Market Share

Market by Segment (2023)

Save over 20% onAnnual Subscription

Key Analytical Findings

Market Dynamics

Market Drivers

Market Opportunities

Market Restraints

Strategic Outlook and Future Directions

Market Value by Segment (2023)

About the Author

Healthcare Research Team

Market Performance Trend

Irritable Bowel Syndrome Treatment Market — Growth Trajectory

Market Size Trend (USD Mn)

Market Dimensions

How this market is segmented

Geographic Analysis

Regional market breakdown

Problem Definition

Secondary Research

Primary Research

Data Analysis

Insights & Reporting

Research Depth

Historical vs. Forecast Data

Competitive Landscape & Porter's Five Forces

Irritable Bowel Syndrome Treatment Market — Competitive Analysis

Regional Market Data

Segment Revenue (2023)

Segment Market Share

Market by Segment (2023)

Save over 20% onAnnual Subscription

Key Analytical Findings

Market Dynamics

Market Drivers

Market Opportunities

Market Restraints

Strategic Outlook and Future Directions

Market Value by Segment (2023)

About the Author

Healthcare Research Team

Save over 20% on
Annual Subscription

Save over 20% on
Annual Subscription